Assenagon Asset Management S.A. Purchases New Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Assenagon Asset Management S.A. purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONSFree Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 184,401 shares of the company’s stock, valued at approximately $9,329,000. Assenagon Asset Management S.A. owned about 0.13% of Ionis Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Peoples Bank KS bought a new position in Ionis Pharmaceuticals during the third quarter valued at approximately $39,000. Almanack Investment Partners LLC. bought a new position in Ionis Pharmaceuticals during the third quarter valued at approximately $44,000. Quantbot Technologies LP bought a new position in Ionis Pharmaceuticals during the second quarter valued at approximately $44,000. Captrust Financial Advisors boosted its stake in Ionis Pharmaceuticals by 21.1% during the second quarter. Captrust Financial Advisors now owns 1,429 shares of the company’s stock valued at $53,000 after buying an additional 249 shares during the last quarter. Finally, Horizon Investments LLC boosted its stake in Ionis Pharmaceuticals by 29.6% during the second quarter. Horizon Investments LLC now owns 1,736 shares of the company’s stock valued at $71,000 after buying an additional 397 shares during the last quarter. 93.86% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Price Performance

IONS opened at $43.35 on Friday. The business has a fifty day moving average of $46.41 and a 200 day moving average of $47.45. Ionis Pharmaceuticals, Inc. has a 52-week low of $34.32 and a 52-week high of $54.44. The company has a quick ratio of 5.83, a current ratio of 5.90 and a debt-to-equity ratio of 3.18. The stock has a market cap of $6.32 billion, a P/E ratio of -16.93 and a beta of 0.40.

Ionis Pharmaceuticals (NASDAQ:IONSGet Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.72. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The company had revenue of $325.00 million during the quarter, compared to analysts’ expectations of $176.01 million. During the same quarter in the previous year, the business earned ($0.37) EPS. Ionis Pharmaceuticals’s revenue was up 113.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.92 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on IONS shares. Oppenheimer increased their price target on Ionis Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, March 6th. Royal Bank of Canada lifted their target price on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, January 26th. Stifel Nicolaus lifted their target price on Ionis Pharmaceuticals from $45.00 to $50.00 and gave the stock a “hold” rating in a report on Monday, December 18th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, February 22nd. Finally, Bank of America upgraded Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $52.00 to $62.00 in a report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $55.67.

Check Out Our Latest Analysis on Ionis Pharmaceuticals

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Eugene Schneider sold 8,000 shares of Ionis Pharmaceuticals stock in a transaction on Friday, January 12th. The stock was sold at an average price of $53.50, for a total transaction of $428,000.00. Following the completion of the sale, the executive vice president now directly owns 38,170 shares of the company’s stock, valued at approximately $2,042,095. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Ionis Pharmaceuticals news, EVP Onaiza Cadoret-Manier sold 5,564 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $50.42, for a total transaction of $280,536.88. Following the completion of the sale, the executive vice president now directly owns 33,810 shares of the company’s stock, valued at approximately $1,704,700.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Eugene Schneider sold 8,000 shares of Ionis Pharmaceuticals stock in a transaction on Friday, January 12th. The shares were sold at an average price of $53.50, for a total value of $428,000.00. Following the sale, the executive vice president now directly owns 38,170 shares of the company’s stock, valued at $2,042,095. The disclosure for this sale can be found here. Insiders sold a total of 101,734 shares of company stock valued at $5,152,226 in the last ninety days. Corporate insiders own 2.65% of the company’s stock.

Ionis Pharmaceuticals Profile

(Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

See Also

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.